Kyoto, Japan

Noriko Nakano

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Daito Chemix Corporation, Kyoto University. Active years: 2015.


% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Noriko Nakano: Innovator in Eye Disease Treatment

Introduction

Noriko Nakano is a prominent inventor based in Kyoto, Japan. She has made significant contributions to the field of ophthalmology, particularly in the treatment of eye diseases. Her innovative work has led to the development of a pharmaceutical agent that addresses critical conditions affecting vision.

Latest Patents

Noriko Nakano holds a patent for an agent effective in treating eye diseases. This invention provides pharmaceutical compositions that are particularly effective for conditions such as glaucoma, especially normal tension glaucoma, and retinitis pigmentosa. The patent outlines methods for preparing these pharmaceuticals and their application in treating various eye diseases. The compound described in the patent is defined by a specific formula, where R is detailed in the description.

Career Highlights

Throughout her career, Noriko Nakano has worked with notable organizations, including Daito Chemix Corporation and Kyoto University. Her experience in these institutions has allowed her to advance her research and contribute to the scientific community significantly.

Collaborations

Noriko has collaborated with esteemed colleagues such as Akira Kakizuka and Seiji Hori. These partnerships have fostered innovation and have been instrumental in her research endeavors.

Conclusion

Noriko Nakano's contributions to the treatment of eye diseases exemplify her dedication to improving healthcare through innovation. Her patent and collaborative efforts highlight her role as a leading inventor in her field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…